Recharacterizing the Metabolic State of Energy Balance in Thrifty and Spendthrift Phenotypes.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 22 11 2019
accepted: 26 02 2020
pubmed: 3 3 2020
medline: 4 2 2021
entrez: 3 3 2020
Statut: ppublish

Résumé

The human thrifty phenotype hypothesis presupposes that lower 24-hour (24h) energy expenditure (24EE) during famine preserves body mass and promotes survival. The prevailing view defines thrifty individuals as having a lower 24EE during fasting. However, it is also plausible that the greater decline in 24EE during fasting in thrifty individuals is due to higher 24EE during energy balance conditions (ENBAL). Herein, we provide evidence that this is indeed the case. In 108 healthy subjects, 24EE was measured in a whole-room indirect calorimeter both during ENBAL and 24h fasting conditions. Subjects were categorized as thrifty or spendthrift based on the median value (-162 kcal/day) of the difference in 24EE (adjusted for body composition) between fasting and ENBAL conditions. Concomitant 24h urinary catecholamines were assessed by liquid chromatography-mass spectrometry. Compared to ENBAL, 24EE decreased during 24h fasting by 172 kcal/day (standard deviation = 93; range, -470 to 122). A greater-than-median decrease in 24EE ("thriftier" phenotype) was due to higher 24EE during ENBAL (+124 kcal/day; P < 0.0001) but not to lower 24EE during fasting (P = 0.35). Greater fasting-induced increase in epinephrine was associated with concomitant lower decrease in 24EE (r = 0.27; P = 0.006). The greater decrease in 24EE during acute fasting (which characterizes the thrifty phenotype) is not due to reduced metabolic rate during fasting but to a relatively higher 24EE during feeding conditions, and this decrease in 24EE during fasting is accompanied by a smaller increase in epinephrine. These results recharacterize the prevailing view of the short-term 24EE responses that define the human metabolic phenotypes. Clinical Trials: NCT00523627, NCT00687115, NCT02939404.

Identifiants

pubmed: 32118268
pii: 5771299
doi: 10.1210/clinem/dgaa098
pmc: PMC7341172
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00523627', 'NCT00687115', 'NCT02939404']

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Published by Oxford University Press on behalf of the Endocrine Society 2020.

Références

Metabolism. 2019 Jan;90:44-51
pubmed: 30385380
Diabetes Care. 2015 Jan;38 Suppl:S8-S16
pubmed: 25537714
J Clin Invest. 1987 Jan;79(1):207-13
pubmed: 3540009
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4481-4491
pubmed: 31305927
J Clin Endocrinol Metab. 2015 Aug;100(8):3011-20
pubmed: 26086330
Thyroid. 2019 Sep;29(9):1209-1219
pubmed: 31298652
J Endocrinol Invest. 2018 Jan;41(1):83-89
pubmed: 28741280
Diabetes. 2015 Aug;64(8):2859-67
pubmed: 25964395
Am J Physiol. 1984 Jul;247(1 Pt 1):E35-40
pubmed: 6742188
Am J Physiol. 1987 Sep;253(3 Pt 1):E322-30
pubmed: 3631260
J Clin Endocrinol Metab. 2017 Jan 1;102(1):279-289
pubmed: 27820654
Am J Clin Nutr. 1967 Nov;20(11):1212-22
pubmed: 6057588
Ann Intern Med. 1980 May;92(5):663-80
pubmed: 6247947
Am J Clin Nutr. 2013 Jan;97(1):7-14
pubmed: 23193010
Int J Obes (Lond). 2014 Feb;38(2):243-51
pubmed: 23736368
Int J Obes. 1982;6(1):23-8
pubmed: 7068313
Proc Natl Acad Sci U S A. 2016 May 24;113(21):E3029-38
pubmed: 27092009
Cell Metab. 2016 Mar 8;23(3):427-40
pubmed: 26959184
Diabetes. 1974 Jan;23(1):1-8
pubmed: 4203518
Diabetes Metab J. 2014 Aug;38(4):245-51
pubmed: 25215270
Br J Nutr. 1994 Mar;71(3):437-47
pubmed: 8172872
Dis Model Mech. 2012 Sep;5(5):608-13
pubmed: 22915022
Trends Endocrinol Metab. 2019 Aug;30(8):491-504
pubmed: 31248786
Am J Clin Nutr. 2019 Sep 1;110(3):593-604
pubmed: 31172178
J Clin Endocrinol Metab. 2006 Feb;91(2):665-70
pubmed: 16303838
Am J Physiol. 1990 Jan;258(1 Pt 2):R87-93
pubmed: 2405717
Am J Clin Nutr. 2000 Jun;71(6):1511-5
pubmed: 10837292
Cell Metab. 2007 Jun;5(6):415-25
pubmed: 17550777
J Clin Endocrinol Metab. 2011 Jun;96(6):E972-6
pubmed: 21450984
Metabolism. 1990 May;39(5):502-10
pubmed: 2186256
Am J Clin Nutr. 2007 Sep;86(3):625-32
pubmed: 17823426
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):497-508
pubmed: 16705481
J Clin Invest. 1986 Dec;78(6):1568-78
pubmed: 3782471
J Lab Clin Med. 1973 Mar;81(3):421-30
pubmed: 4686958
Metabolism. 2018 May;82:65-71
pubmed: 29305947
Am J Physiol. 1987 Feb;252(2 Pt 1):E189-96
pubmed: 3548419
Cell Metab. 2013 Sep 3;18(3):333-40
pubmed: 24011069
Obesity (Silver Spring). 2019 May;27(5):691-699
pubmed: 31012296
Nutr Res Rev. 1995 Jan;8(1):225-42
pubmed: 19094287
Diabetes. 2013 Dec;62(12):4043-51
pubmed: 23974925
Br J Nutr. 2019 Oct 11;:1-27
pubmed: 31601285
J Clin Endocrinol Metab. 2013 Apr;98(4):E703-7
pubmed: 23418317
Ann N Y Acad Sci. 2014 Apr;1311:77-87
pubmed: 24697152
J Endocrinol. 2014 Oct;223(1):T83-96
pubmed: 25063755
Cell Rep. 2016 Jul 19;16(3):707-16
pubmed: 27396336
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 32118268
J Clin Invest. 2014 Sep;124(9):3913-22
pubmed: 25133427
Acta Med Scand. 1977 Jan;201(1-2):15-22
pubmed: 835366
Nutr Diabetes. 2019 Aug 8;9(1):22
pubmed: 31395858
Am J Clin Nutr. 2013 May;97(5):990-4
pubmed: 23535105
Int J Obes (Lond). 2016 May;40(5):754-60
pubmed: 26499440
Am J Clin Nutr. 2017 Nov;106(5):1206-1212
pubmed: 28877891
J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):698-706
pubmed: 18693224
Int J Obes Relat Metab Disord. 2001 Oct;25(10):1481-6
pubmed: 11673770
Diabetes. 2019 Feb;68(2):318-323
pubmed: 30257977
Am J Clin Nutr. 1956 Mar-Apr;4(2):169-75
pubmed: 13302165
Clin Sci (Lond). 1985 Jun;68(6):613-9
pubmed: 2485261
J Clin Invest. 2015 Nov 03;125(12):4601-11
pubmed: 26529252
Am J Physiol Regul Integr Comp Physiol. 2017 Jun 1;312(6):R938-R947
pubmed: 28356295
Int J Obes (Lond). 2019 Jul;43(7):1456-1465
pubmed: 30651576
Diabetes. 2015 Nov;64(11):3680-9
pubmed: 26185280
Cell Metab. 2017 Apr 4;25(4):935-944.e4
pubmed: 28380381
Int J Obes Relat Metab Disord. 2001 May;25(5):593-600
pubmed: 11360139
J Clin Endocrinol Metab. 2013 Jul;98(7):2791-9
pubmed: 23666976
Int J Obes (Lond). 2019 Feb;43(2):233-242
pubmed: 29717270
J Clin Invest. 2003 May;111(9):1409-21
pubmed: 12727933
Am J Clin Nutr. 1987 Oct;46(4):557-62
pubmed: 3661473

Auteurs

Tim Hollstein (T)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Alessio Basolo (A)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Takafumi Ando (T)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Susanne B Votruba (SB)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Mary Walter (M)

Clinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.

Jonathan Krakoff (J)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Paolo Piaggi (P)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.
Department of Information Engineering, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH